Roth Capital Forecasts biote’s Q1 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for biote in a report released on Thursday, May 8th. Roth Capital analyst G. Kelly expects that the company will post earnings of $0.15 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.20 EPS and Q4 2026 earnings at $0.21 EPS.

Separately, Craig Hallum reduced their price objective on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

biote Stock Performance

BTMD opened at $3.99 on Monday. The business’s fifty day moving average is $3.61 and its two-hundred day moving average is $4.93. The company has a market cap of $218.29 million, a price-to-earnings ratio of 15.35 and a beta of 1.17. biote has a one year low of $3.04 and a one year high of $8.44.

biote (NASDAQ:BTMD) last posted its earnings results on Wednesday, May 7th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $48.99 million for the quarter, compared to the consensus estimate of $47.25 million. biote had a negative return on equity of 32.41% and a net margin of 5.20%.

Institutional Trading of biote

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD purchased a new position in biote during the fourth quarter worth about $67,000. Commonwealth Equity Services LLC purchased a new position in biote during the fourth quarter worth about $68,000. Public Employees Retirement System of Ohio purchased a new position in biote during the fourth quarter worth about $69,000. Intech Investment Management LLC purchased a new position in biote during the fourth quarter worth about $71,000. Finally, SG Americas Securities LLC purchased a new position in biote during the fourth quarter worth about $76,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, major shareholder Guines Llc acquired 8,801 shares of biote stock in a transaction dated Monday, April 21st. The shares were acquired at an average cost of $3.27 per share, for a total transaction of $28,779.27. Following the completion of the transaction, the insider now directly owns 4,173,101 shares of the company’s stock, valued at $13,646,040.27. The trade was a 0.21% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Stephen Mark Cone acquired 38,104 shares of biote stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $3.88 per share, for a total transaction of $147,843.52. Following the completion of the transaction, the director now directly owns 160,829 shares of the company’s stock, valued at approximately $624,016.52. This represents a 31.05% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 1,412,080 shares of company stock worth $4,598,190 over the last three months. 24.00% of the stock is currently owned by corporate insiders.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.